

## CpG ODN 10101

<b>Cat. No.:</b>	HY-150217
<b>CAS No.:</b>	1234402-77-7
<b>Molecular Weight:</b>	6702.37
<b>Sequence:</b>	DNA, d(P-thio)(T-C-G-T-C-G-T-T-T-T-C-G-C-G-C-G-C-C-G)
<b>Target:</b>	Toll-like Receptor (TLR); HCV
<b>Pathway:</b>	Immunology/Inflammation; Anti-infection
<b>Storage:</b>	-20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

## CpG ODN 10101

### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : ≥ 25 mg/mL (3.73 mM)  
\* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	0.1492 mL	0.7460 mL	1.4920 mL
	5 mM	---	---	---
	10 mM	---	---	---

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

CpG ODN 10101, a synthetic oligodeoxynucleotide (ODN), is a toll-like receptor 9 (TLR9) agonist. CpG ODN 10101 is a potent inducer of cytokine/chemokine expression ex vivo when used in combination with HH2(VQLRIRVAVIRA-NH<sub>2</sub>). CpG ODN 10101 induces IFN- secretion from dendritic cells (DCs) and stimulates B-cells. CpG ODN 10101 has antiviral and immunomodulatory properties that can influence chronic infection with HCV<sup>[1][2]</sup>.

#### IC<sub>50</sub> & Target

TLR9

### REFERENCES

- [1]. Jason Kindrachuk, et al. A novel vaccine adjuvant comprised of a synthetic innate defence regulator peptide and CpG oligonucleotide links innate and adaptive immunity. *Vaccine*. 2009 Jul 23;27(34):4662-71.
- [2]. John G McHutchison, et al. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. *Hepatology*. 2007 Nov;46(5):1341-9.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA